Hotgen(688068) 搜狐财经·2025-03-26 11:46Company Overview - Beijing Hotgen Biotech Co., Ltd. focuses on innovative biotechnology, providing solutions from early disease screening and diagnosis to treatment [1] - The main products include in vitro diagnostic products and innovative biopharmaceuticals [1] Financial Performance - For the third quarter of 2024, the company reported revenue of 386 million yuan, a year-on-year decrease of 5.10% [1] - The net profit for the same period was -40.64 million yuan, representing a year-on-year decline of 174.73% [1] - The gross profit margin stood at 52.44% [1] Market Position - As of the latest report, the company has a market capitalization of 7.861 billion yuan and a price-to-book ratio of 2.41 [1] - There are 19 institutional investors holding shares in Hotgen Biotech, with a total holding of 6.6764 million shares valued at 413 million yuan [1] Industry Comparison - The average price-to-earnings (P/E) ratio for the industry is 45.14 (trailing twelve months) and 49.52 (static), while Hotgen Biotech's P/E ratios are -43.86 for both [2] - The industry median P/E ratios are 31.99 (trailing twelve months) and 31.00 (static), with a price-to-book ratio of 2.48 [2]